Thrombolytic therapy administered longer after the onset of ischemic stroke than current recommendations did not demonstrate improved clinical outcomes as compared to placebo, according to a recent trial published in the New England Journal of Medicine.
Minjee Kim, MD, associate professor in the Ken and Ruth Davee Department of Neurology’s Division of Neurocritical Care, was a co-author of the study.
Ischemic stroke occurs when a blood vessel supplying blood to the brain is blocked or reduced, and accounts for nearly 90% of all strokes, according to statistics from the American Stroke Association.
Comments are closed.